Recombinant Mouse Anti-H3N2 HA Antibody (S139/1) (CAT#: PABZ-195)

Figure 1 Binding and neutralization breadth of influenza HA strains by S139/1 Fab and IgG

Lee, P. S., Yoshida, R., Ekiert, D. C., Sakai, N., Suzuki, Y., Takada, A., & Wilson, I. A. (2012). Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proceedings of the National Academy of Sciences, 201212371.

Figure 2 HA sequence variation at the S139/1 epitope

Lee, P. S., Yoshida, R., Ekiert, D. C., Sakai, N., Suzuki, Y., Takada, A., & Wilson, I. A. (2012). Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proceedings of the National Academy of Sciences, 201212371.

Figure 3 Reactivity of MAb S139/1 to various influenza virus strains.

Binding activity of MAb S139/1 at the concentrations of 100 µg/ml (grey), 10 µg/ml (white), and 1 µg/ml (black) to the indicated virus strains was measured by ELISA.

Yoshida, R., Igarashi, M., Ozaki, H., Kishida, N., Tomabechi, D., Kida, H., ... & Takada, A. (2009). Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS pathogens, 5(3), e1000350.

Figure 4 Neutralization activity of MAb S139/1 to various HA subtypes of influenza A virus strains.

Viruses were mixed with indicated concentrations of the purified MAb S139/1 (A) or control IgG2a (ZGP12/1.1) (B). Neutralization activities were evaluated by plaque reduction assays using MDCK cells.

Yoshida, R., Igarashi, M., Ozaki, H., Kishida, N., Tomabechi, D., Kida, H., ... & Takada, A. (2009). Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS pathogens, 5(3), e1000350.

Figure 5 HI activity of MAb S139/1 with various influenza virus strains.

Yoshida, R., Igarashi, M., Ozaki, H., Kishida, N., Tomabechi, D., Kida, H., ... & Takada, A. (2009). Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS pathogens, 5(3), e1000350.

Figure 6 Protective efficacy of passive immunization with MAb S139/1 in mice.

Mice were passively immunized before (A) or after (B) virus challenge with Aichi (H3) or WSN (H1). Control mice were given MAb ZGP12/1.1 or PBS. Virus titers of the lung were determined by a plaque assay. The means and standard deviations are shown. For statistical purposes, samples with undetectable virus titers were given the value 2.0 log₁₀ PFU/g. The data of pre-immunized mice were analyzed using the nonparametric Kruskal-Wallis ANOVA on ranks, followed by the Mann-Whitney U-test with the Bonferroni correction for multiple comparisons. The data of post-immunized mice were analyzed using the Mann-Whitney U-test. Two-sided p values less than 0.05 were considered statistically significant. Significant differences were indicated by asterisks (*** p<0.001, ** p<0.01, * p<0.05). All statistical analyses were performed with the computer program R (version 2.8.1).

Yoshida, R., Igarashi, M., Ozaki, H., Kishida, N., Tomabechi, D., Kida, H., ... & Takada, A. (2009). Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS pathogens, 5(3), e1000350.